Catalyst
Slingshot members are tracking this event:
Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KITE |
|
|
||||
Additional Information
The DLBCL cohort of ZUMA-1 enrolled patients whose disease is chemorefractory (no response to last line of therapy or has relapsed within 12 month of autologous stem cell therapy). Patients received a lymphodepletion regimen that consisted of "low-dose" chemotherapy regimen of cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily for 3 days prior to infusion of the target KTE-C19 dose of 2 x 106 cells/kg.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 07, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Kte-c19, Zuma-1, Diffuse Large B-cell Lymphoma
